Literature DB >> 1879945

Rat model of congenital toxoplasmosis.

J P Dubey1, S K Shen.   

Abstract

A rat model of congenital toxoplasmosis is described for the study of protective immunity and chemotherapy during pregnancy. Six Sprague-Dawley 7- to 15-day gestational rats were inoculated orally (three rats, trial A) or subcutaneously (three rats, trial B) with 10,000 infective oocysts of the CT-1 strain of Toxoplasma gondii. The tissues of rat pups born from these rats were bioassayed for T. gondii infection. T. gondii was recovered from 30 of 33 (90.9%, trial B) and 23 of 28 (82.17%, trial A) rat pups bioassayed at 1 to 134 days of age. Two 10- to 14-day gestational pregnant rats were inoculated subcutaneously (trial C) with 10,000 infective bradyzoites from tissue cysts; 10 of 23 (43.8%) of the newborn pups were infected with T. gondii. Congenital infection occurred only when rats were infected during pregnancy. None of three rats in trial A that had given birth to congenitally infected rat pups produced congenitally infected rat pups during the second pregnancy.

Entities:  

Mesh:

Year:  1991        PMID: 1879945      PMCID: PMC258169          DOI: 10.1128/iai.59.9.3301-3302.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  9 in total

1.  Congenital transmission of toxoplasmosis through successive generations of mice.

Authors:  J K BEVERLEY
Journal:  Nature       Date:  1959-05-09       Impact factor: 49.962

2.  [Fetal infection during the acute and chronic phase of latent toxoplasmosis in rats].

Authors:  T HELLBRUGGE
Journal:  Arch Gynakol       Date:  1955

3.  Experiments on the transmission of toxoplasmosis.

Authors:  J S REMINGTON
Journal:  Surv Ophthalmol       Date:  1961-12       Impact factor: 6.048

Review 4.  Status of toxoplasmosis in sheep and goats in the United States.

Authors:  J P Dubey
Journal:  J Am Vet Med Assoc       Date:  1990-01-15       Impact factor: 1.936

Review 5.  Estimating income losses and other preventable costs caused by congenital toxoplasmosis in people in the United States.

Authors:  T Roberts; J K Frenkel
Journal:  J Am Vet Med Assoc       Date:  1990-01-15       Impact factor: 1.936

6.  Serological responses of equids fed Toxoplasma gondii oocysts.

Authors:  J P Dubey; G Desmonts
Journal:  Equine Vet J       Date:  1987-07       Impact factor: 2.888

7.  Subcutaneous and intestinal vaccination with tachyzoites of Toxoplasma gondii and acquisition of immunity to peroral and congenital toxoplasma challenge.

Authors:  R McLeod; J K Frenkel; R G Estes; D G Mack; P B Eisenhauer; G Gibori
Journal:  J Immunol       Date:  1988-03-01       Impact factor: 5.422

8.  Partially purified antigen preparations of Toxoplasma gondii protect against lethal infection in mice.

Authors:  F G Araujo; J S Remington
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

9.  Resistance to avirulent Toxoplasma gondii in normal and vaccinated rats.

Authors:  E K Pettersen
Journal:  APMIS       Date:  1988-09       Impact factor: 3.205

  9 in total
  6 in total

1.  Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis.

Authors:  Joachim Müller; Adriana Aguado-Martínez; Luis-Miguel Ortega-Mora; Javier Moreno-Gonzalo; Ignacio Ferre; Matthew A Hulverson; Ryan Choi; Molly C McCloskey; Lynn K Barrett; Dustin J Maly; Kayode K Ojo; Wes Van Voorhis; Andrew Hemphill
Journal:  J Antimicrob Chemother       Date:  2017-08-01       Impact factor: 5.790

2.  Protective immunity against congenital toxoplasmosis with recombinant SAG1 protein in a guinea pig model.

Authors:  M Haumont; L Delhaye; L Garcia; M Jurado; P Mazzu; V Daminet; V Verlant; A Bollen; R Biemans; A Jacquet
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

3.  Rat model of congenital toxoplasmosis: rate of transmission of three Toxoplasma gondii strains to fetuses and protective effect of a chronic infection.

Authors:  L Zenner; F Darcy; M F Cesbron-Delauw; A Capron
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

4.  Great efficacy of sulfachloropyrazine-sodium against acute murine toxoplasmosis.

Authors:  Yan-Bo Zeng; Shun-Hai Zhu; Hui Dong; Hong-Yu Han; Lian-Lian Jiang; Quan Wang; Jun Cheng; Qi-Ping Zhao; Wei-Jiao Ma; Bing Huang
Journal:  Asian Pac J Trop Biomed       Date:  2012-01

Review 5.  Animal models of intellectual disability: towards a translational approach.

Authors:  Carla A Scorza; Esper A Cavalheiro
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

6.  The Ultrastructural Effects of Sulfachloropyrazine on Toxoplasma gondii Tachyzoites.

Authors:  Yb Zeng; H Dong; Hy Han; Ll Jiang; Qp Zhao; Sh Zhu; Wj Ma; J Cheng; B Huang
Journal:  Iran J Parasitol       Date:  2013-01       Impact factor: 1.012

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.